Pulmonx Corporation (LUNG)

6,34 +0,17 (+2,76%) Börsenschluss: 04:00PM EDT

Pulmonx Corporation

700 Chesapeake Drive
Redwood City, CA 94063
United States
650 364 0400
https://pulmonx.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 279

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. David A. Lehman	General Counsel & Secretary	651,39k	N/A	1961
Mr. Geoffrey Beran Rose	Chief Commercial Officer	632,29k	N/A	1974
Mr. Steven S. Williamson	CEO, President & Director	N/A	N/A	1973
Mr. Mehul Joshi	Chief Financial Officer	N/A	N/A	1961
Mr. Sri Radhakrishnan	Chief Technical Officer	N/A	N/A	N/A
Ms. Marcee M. Maroney	Vice President of Marketing	N/A	N/A	1970
Sarah Huber	Vice President of Sales (U.S.)	N/A	N/A	N/A
Ms. Lisa Paul	Chief People Officer	N/A	N/A	1964
Mr. Jérôme Erath	Senior VP & GM of Europe Middle-East & Africa	N/A	N/A	N/A
Mr. John B. McKune	VP & Corporate Controller	N/A	N/A	1976

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Corporate Governance

Pulmonx Corporations ISS Governance QualityScore, Stand 29. Juni 2024, lautet 9. Die grundlegenden Scores sind Audit: 4, Vorstand: 6, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.